A novel oral budesonide formulation is highly effective for induction of remission in patients with active eosinophilic esophagitis: Results from the 6-weeks open-label treatment phase of EOS-2 trial

(1) Hospital General de Tomelloso,Tomelloso,Spain

(2) Technische Universität München,München,Germany

(3) Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany

(4) USZ Zürich,Zürich,Switzerland

(5) Hospital Universitario de La Princesa,Madrid,Spain

(6) Sana Klinikum Lichtenberg,Berlin,Germany

(7) St. George`s University Hospitals,London,United Kingdom

(8) Universitätsspital Basel,Basel,Switzerland

(9) Hospital 12 de Octubre Dept. de Gastroenterologia,Madrid,Spain

(10) Academisch Med. Centrum Amsterdam,Amsterdam,Netherlands

(11) Klinikum Bayreuth Abt. Pathology,Bayreuth,Germany

(12) Dr. Falk Pharma GmbH,Freiburg,Germany

(13) Swiss EoE Research Network,Olten,Switzerland

This item was part of the What's hot in eosinophilic oesophagitis (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

You may be interested in:

Role of endoscopy and histology
English, Presentation, Oesophagus, Histopathology, Immunology, Paediatrics, Young GI Track, 2018
All patients with reflux symptoms should be biopsied to rule out Eosinophilic oesophagitis
English, Presentation, Oesophagus, 2016, Endoscopy, Neurogastroenterology & Motility, Paediatrics


  • Format
    • Abstract
  • Year
    • 2019